Your partner in dilation reversal
The only commercially available FDA‑approved product that reverses pharmacologically-induced mydriasis.1
Order Now
RYZUMVI is the first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist approved to reverse pharmacologically-induced mydriasis.1
RYZUMVI reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle, thereby reducing pupil diameter, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.1
The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.1
Order RYZUMVI today
Select from these Authorized Distributors:
With RYZUMVI, you may be able to offer faster eye dilation reversal to help address patient concerns and improve the post-dilation experience.1*
Not actual patients.
With RYZUMVI—dilation may not need to disrupt your patient's entire day.1-3
The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.
Ready to discuss your needs with Viatris?
Fill in our request form and a representative will contact you soon.
All fields required